Skip to content

Author

E. Asarkaya

1 paper indexed here

We haven’t gathered this author’s papers yet. Follow them and we’ll fetch their work.

Not the right person? Other researchers publish under this name.

Open access Aug 2026

EZH2 Expression and Clinical Outcomes in Non-Small Cell Lung Cancer Patients Treated with Immune Checkpoint Inhibitors: A Real-World Retrospective Cohort Study

Background: Lung cancer remains the leading cause of cancer-related mortality, with non-small cell lung cancer (NSCLC) accounting for approximately 85% of cases. Over the past decade, immune checkpoint inhibitors have become a core component of first-line treatment for advanced-stage NSCLC lacking driver mutations. Pro...

E. Asarkaya, Hatice Asoglu, Abdurrahman Aykut et al. · 0 citations

We use cookies to run the site and, with your consent, for analytics and to show ads. See our Cookie Policy.